Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Biotechnology
Updated Oct 3, 2026
AI dilution summary: the dominant contractual driver and its mechanism, then each further driver ranked, for Signal8 Pro subscribers.
